Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Chemed (CHE)

Chemed Q1 2024 revenue rises 5.2% to $589.2 million; GAAP EPS up 18.4% to $4.24

Positive Impact 3 of 5 earnings Written later

Chemed reported first-quarter 2024 revenue of $589.2 million, up 5.2%, and GAAP diluted EPS of $4.24, up 18.4%, with VITAS driving the gains while Roto-Rooter revenue fell 5.8%. The company reiterated its full-year 2024 adjusted EPS guidance range of $23.30 to $23.70 and said it will provide updated guidance with its June 30, 2024 results.

Key points

  • Consolidated revenue rose 5.2% to $589.2 million; adjusted diluted EPS was $5.20, up 21.5%.
  • VITAS net patient revenue rose 14.0% to $354.0 million, and its adjusted EBITDA excluding Medicare Cap rose 67.2% to $60.7 million.
  • Roto-Rooter revenue fell 5.8% to $235.2 million, and its adjusted EBITDA declined 15.6%.
  • Full-year 2024 adjusted EPS guidance of $23.30 to $23.70 was reiterated; cash and equivalents were $313.4 million at March 31, 2024, with no debt.

The filing

CompanyChemed (CHE)
Form8-K, current report
Filed with the SECApr 24, 2024, 4:16 PM ET
Accession number0001562762-24-000096

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 24, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.